Astrazeneca plc Dossier
Qualitative Analysis
Business overview
AstraZeneca plc is a global, science-led, patient-focused biopharmaceutical company specializing in the discovery, development, manufacture, and commercialization of prescription medicines. The company operates across major therapeutic areas, including Oncology, Rare Disease, and BioPharmaceuticals (which encompasses Cardiovascular, Renal, and Metabolism (CVRM), Respiratory & Immunology, and Vaccines & Immune Therapies). AstraZeneca is renowned for its robust R&D engine, supporting a pipeline of nearly 200 projects and 16 blockbuster medicines. The company leverages advanced therapeutic modalities, such as antibody-drug conjugates (ADCs) and cell therapies, alongside enterprise-wide artificial intelligence to optimize drug discovery and commercial operations.
Research as of 29 Jul 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
AstraZeneca's long-term strategic plan to launch at least 20 new medicines and achieve $80 billion in Total Revenue by 2030, with sustained growth thereafter.
Expected impact: Establishes industry-leading growth across oncology, biopharmaceuticals, and rare diseases while transforming patient outcomes globally.
Flagship environmental sustainability programme aimed at decarbonising AstraZeneca's operations and value chain, including a target to reduce Scope 1 and Scope 2 greenhouse gas (GHG) emissions by 98% by 2026 from a 2015 baseline.
Expected impact: Achieves near-zero operational emissions and drives the delivery of net-zero healthcare, including transitioning inhaled medicines to next-generation propellants with 99.9% lower global warming potential starting in 2025.
Strategic plan to expand medicines manufacturing and R&D footprint in China, building on existing global strategic R&D centres in Beijing and Shanghai.
Expected impact: Strengthens local supply chain resilience, enhances regional R&D capabilities, and secures long-term growth in one of the company's key emerging markets.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
To embed Modella AI's multi-modal foundation models and AI agents into AstraZeneca's oncology R&D environment, speeding up drug development and clinical processes.
Financial impact: Financial terms of the acquisition were undisclosed.
Acquisition of AbelZeta's 50% share of the China development and commercialisation rights to C-CAR031, an autologous, GPC3-targeting CAR-T cell therapy, giving AstraZeneca sole global rights.
Financial impact: AbelZeta is eligible to receive up to $630 million, including an upfront payment and development, regulatory, and sales milestones.
Acquisition of EsoBiotec to strengthen AstraZeneca's capabilities in oncology and genetic medicine platforms.
Financial impact: Disclosed transaction value of approximately $1.0 billion.
Strategic Partnerships
Strengthens AstraZeneca's weight management and obesity portfolio by securing exclusive global rights (outside of China) to CSPC's once-monthly injectable weight management portfolio, including clinical-ready asset SYH2082.
Terms: AstraZeneca paid an upfront payment of $1.2 billion. CSPC is eligible to receive up to $3.5 billion in development and regulatory milestones, plus up to $13.8 billion in sales milestones and tiered royalties.
Acquisition of worldwide rights to develop and commercialise Zegfrovy (sunvozertinib), a novel oral irreversible EGFR inhibitor approved in the US and China for adult patients with locally advanced or metastatic EGFR exon 20 insertion mutation non-small cell lung cancer (NSCLC).
Terms: AstraZeneca will make an upfront payment of $600 million and additional milestone payments of up to $900 million.
Exclusive license for the development, manufacturing, and commercialisation of CTTQ's PDE3/4 inhibitor, TQC3721, which is being developed for respiratory indications.
Terms: Upfront payment of $200 million, with additional development, regulatory, and sales milestones of up to $1.9 billion.
Secures exclusive development and commercialisation rights outside of China for Jacobio's proprietary Pan-KRAS inhibitor JAB-23E73, with joint development and commercialisation rights within China.
Terms: Jacobio received an upfront payment of $100 million and is eligible for additional development and commercial milestones of up to $1.9 billion, plus tiered royalties ex-China.